This web site is not optimized for Internet Explorer 6. You may notice
decreased functionality compared to other web browsers. Please follow the
link below to upgrade to a new version of Internet Explorer.

The "Yes" link below will take you out of the Abbott Laboratories family of websites.
Links which take you out of Abbott Laboratories worldwide web sites are not under the
control of Abbott Laboratories, and Abbott Laboratories is not responsible for the
contents of any such site or any further links from such site. Abbott Laboratories is
providing these links to you only as a convenience, and the inclusion of any link does
not imply endorsement of the linked site by Abbott Laboratories.

Do you wish to leave this site?
Coronary Bioresorbable Vascular Scaffolds

Absorb Bioresorbable Vascular Scaffold System

Indications & Important Safety Information ››


Absorb, the 4th Revolution in Interventional Cardiology

Absorb is  a Bioresorbable Vascular Scaffold (BVS) system that elutes everolimus in a similar way to XIENCE V and then resorbs naturally into the body leaving no permanent scaffold*. Absorb is comprised of four key design elements: a bioresorbable scaffold, a bioresorbable coating, everolimus and the XIENCE V delivery system.


Absorb Design Elements

Absorb design

Absorb  defines a new paradigm - Vascular Reparative Therapy (VRT). VRT is designed to restore the vessel to a more natural state§, making natural vascular function possible.  While stenting performance is characterized by a single phase of revascularisation, Absorb was designed with the premise of working in three phases to deliver VRT:

  • Revascularisation
  • Restoration
  • Resorption



In the Revascularisation phase, Absorb revascularises like a best in class DES, XIENCE. Absorb achieves this goal by offering good deliverability, excellent conformability, a minimum of acute recoil, high radial strength, and controlled release of the anti-proliferative drug everolimus to minimise neointimal growth.

Restoration & Resorption

The goal of the restoration phase is to enable natural vessel function for improved long-term outcomes. Restoration of the vessel occurs as the scaffold benignly resorbs without inflammation. Absorb gradually ceases providing luminal support and evolves from an intact scaffold to a discontinuous structure embedded within neointimal tissue. As the scaffold degrades, the polymer is converted into lactic acid which is metabolised through the Krebs cycle and is ultimately converted into benign by-products of carbon dioxide and water.

*Small platinum markers at scaffold edges remain for fluoroscopic landmarking.
All illustrations are artists’ renditions.
§Versus current standard of care, DES.


Vascular Reparative Therapy (VRT) Heralds a New Era in Interventional Cardiology

The development of Bioresorbable Vascular Scaffolds was based on the premise that scaffolding and drug delivery to the diseased coronary vessel are only required on a temporary basis following coronary interventions. Several studies support this concept and indicate that there is no incremental clinical benefit of a permanent implant over time1-7. Absorb, the world’s first commercially available drug-eluting coronary Bioresorbable Vascular Scaffold (BVS), is designed to deliver Vascular Reparative Therapy (VRT) by eliminating the presence of a permanent mechanical restraint*. Vascular Reparative Therapy allows for mechanical conditioning, vasomotion and late lumen gain8. Preliminary evidence of vasomotion suggests that natural vessel function is possible to achieve improved long-term outcomes9. Late lumen gain has the potential for reduced TLR by maintaining a widely patent lumen10. The goal of VRT is to ultimately return the vessel back to a more natural state§ with the possibility for delayed disease progression and improved angina control.



*Small platinum markers at scaffold edges remain for fluoroscopic landmarking.

§Versus current standard of care, DES.

1. Serruys PW, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331(8):489-95.
2. Serruys PW, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988;77(2):361-71.
3. Nobuyoshi M, et al. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J Am Coll Cardiol 1988;12(3):616-23.
4. Asakura M, et al. Remodeling of in-stent neointima, which became thinner and transparent over 3 years: serial angiographic and angioscopic follow-up. Circulation 1998;97(20):2003-6.
5. Witkowski A, et al. A randomized comparison of elective high-pressure stenting with balloon angioplasty: six-month angiographic and two-year clinical follow-up. On behalf of AS (Angioplasty or Stent) trial investigators. Am Heart J 2000;140(2):264-71.
6. Betriu A, et al. Randomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. J Am Coll Cardiol 1999;34(5):1498-506.
7. Kandzari DE, et al. Comparison of long-term (seven year) outcomes among patients undergoing percutaneous coronary revascularization with versus without stenting. Am J Cardiol 2006;97(10):1467-72.
8. Serruys PW, et al. From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012;33(1):16-25b.
9. ABSORB Cohort A 24-month and ABSORB Cohort B 12-month vasomotor function testing.
10. Between six months and two years in ABSORB Cohort B.

Post PCI Angina


Post PCI angina




Ordering Information
Absorb is available in seven sizes.

Absorb Order info


AP2937989-OUS Rev. B


Indications and Important Safety Information